Compare Abbott Laboratories (ABT) vs Fortinet Inc (FTNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Fortinet Inc — how do they compare? Abbott Laboratories trades at $95.8 (market cap $166.94B), while Fortinet Inc trades at $155.3 (market cap $116.25B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals.
| ABT | FTNT | |
|---|---|---|
Market Cap | $166.94B | $116.25B |
Sector | Health | Technology |
52-Week High | $136.62 | $162.35 |
52-Week Low | $82.57 | $74.39 |
Enterprise Value | $193.69B | $113.45B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Fortinet (FTNT) trades at $158.67, up 1.55% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with revenue growing to $6.80B in 2025 and net income of $1.85B, though valuation multiples like P/E of 62.93 appear elevated. Recent earnings have consistently beaten expectations, and the company maintains robust profitability with a gross margin of 80.3%. News highlights include AI-driven security growth and upcoming Q2 2026 results announcement on July 29, 2026.
The outlook remains positive due to strong execution and cybersecurity demand, but high valuation and competitive pressures pose risks. Analyst consensus is mixed with a $115.53 price target below current levels, suggesting caution despite bullish technicals. Key risks include execution missteps and market volatility, while institutional sentiment leans neutral with 47.06% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
